Bharat Biotech's Covid-19 shot safe, produced immune response in early human trial: The Lancet

The vaccine, developed with the Indian Council of Medical Research (ICMR), is being evaluated in a separate 25,800 person trial, which started in November.

Indian drugmaker Bharat Biotech’s coronavirus vaccine, which has been authorized for use in the country, proved safe and produced an immune response in a small group of adults aged 18 to 55, according to a study published in The Lancet medical journal.